in the rate-limiting enzyme of BH 4 synthesis, develop PH phenotype under normoxic conditions without concomitant systemic hypertension. While deficiency of BH 4 causes selective pulmonary pathology, highlighting its importance in pulmonary vascular homeostasis, administration of BH 4 attenuates hypoxic pulmonary vasoconstriction and causes pulmonary vasodilation via NO and hydrogen peroxide production and its strong antioxidant properties. 19 Cardiac function is influenced by eNOS activity. [20] [21] [22] [23] Pressure overload reduces cardiac BH 4 in conjunction with eNOS uncoupling leading to dilatory remodeling, left ventricular hypertrophy, and fibrosis. 24 ,25 BH 4 treatment ameliorated preexisting left ventricular hypertrophy and fibrosis. 26 Whether the right ventricle behaves the same in response to pressure overload in PH, is yet to be explored.
Thus, we hypothesize that BH 4 may target the pulmonary vasculature directly and consequently the right heart function as well as independently by its effects on the myocytes function. We tested this hypothesis by examining the acute pharmacological effects of BH 4 in isolated heart systems independent of those on pulmonary circulation; furthermore, we evaluated the effect and the mechanism of chronic BH 4 treatment aiming at prevention and reversal of the experimental monocrotaline (MCT) model of PH.
| METHODS

| Animals
Two animal models were used. The first model is the MCT-induced PH rat model in Male Sprague Dawley rats (250 g) from Charles River (Margate, UK), which were used for two treatment protocols of prevention and rescue approach. MCT model of PH is widely used; the alkaloid MCT (60 mg/kg) (Sigma-Aldrich, Irvine, UK) was injected subcutaneously to rats weighing 230-250 g. 27 Normal saline was injected as control. Rats were treated according to the specific protocol and their well-being and body weight followed daily. MCT injection induces a gradual development of severe PH phenotype within 2-4 weeks. The second animal model is a genetic mouse model called the Hph-1 mice, which is deficient in guanosine triphosphate (GTP)-cyclohydrolase causing severe BH4 deficiency, was generated by ENU mutagenesis and mice at the age of 5-7 months (males:females 1:1)
were used for mice experiments. Wild-type mice (WT), hph-1 heterozygous (±), and hph-1 homozygous (hph-1) littermates on a C57BL/6 background were obtained by interbreeding hph-1 heterozygotes.
The use of both a genetic and induced model may widen our understanding of the pathophysiological and causative role of BH 4 in PH as discussed below. All the animal experiments were approved by the university ethics review board as they were conducted in accordance with UK Home Office Animals (Scientific Procedures) Act 1986. were recorded continuously for another 5 minutes.
| Hph-1 mice right ventricular characterization
| On cardiac function
The hearts of control and MCT animals were isolated and perfused with Krebs Henseleit buffer (composition in mmol/L: NaCl 118.5, NaHCO3 25, KCl 4.7, MgSO4.7H2O 1.2, KH2PO4 1.2, Glucose 11, CaCl2 (dehydrate) 1.2), in a retrograde manner and constant pressure of 85 mm Hg (the aorta is cannulated, the heart is perfused in retrograde fashion and constant pressure, into the coronary arteries, allowing the heart to beat for several hours, and out of the coronary sinus into the right ventricle and then into the chamber of the oxygenated perfusate in a closed circulation). The hearts had a mean intrinsic pacing rate of around 250 to 300 bpm. A 0.03-cm 3 latex balloon, created in house, filled with water and attached to a pressure transducer was placed in the RV via the right atrium, and pressure traces were sampled at a rate of 4000 Hz by PowerLab system, curves of RV pressure across time were recorded and analyzed with Chart 7 Pro software (ADInstruments Ltd). After a stable baseline period of 15 minutes where the buffer has circulated homogenously in the system (serving as baseline control measurements), BH 4 (in a dose of 10 μg/mL dissolved in the same Krebs Henseliet buffer) was added to the closed circulation and cardiac pressures were continuously recorded.
| Chronic pharmacological effects of BH 4 in rat model of MCT-induced PH
In all experiments, animals were fasted (12 hours at the start of treatment and daily later on for 6-8 hours) to assure proper drug intake.
Rats were kept in separate cages for 30 minutes while feeding drug pellets. Pellet treatment was given once daily. All of the pellets were consumed daily, in a matter of 10-15 minutes separately. All animals had free access to water all the time and to food when not fasted.
They were exposed to a normal 12 hour/12 hour light/dark cycle. The following protocols were designed.
| Safety and tolerability
Total of 20 rats, divided into 4 groups (N = 5), were treated with normal diet, placebo pellets (including all the preservatives and core materials but without BH 4 ), oral pellets of BH 4 (10 mg/kg), and oral pellets of BH 4 (100 mg/kg) for a week. Well-being and body weight were followed up every day and end-stage hemodynamic measurements were taken.
| Preventive treatment
Total of 24 rats were divided into four groups (N = 6 per group).
Treatment was started 5 days before MCT injection and continued for 3 weeks after MCT injection. The groups were as follows: (1) 
| Rescue treatment
Total of 64 rats were divided into 5 groups. Treatment was started 14 days after MCT injection and continued for another 2 weeks. The groups were as follows: (1) The differences in group numbers resulted from pooling many animal studies performed during this research project, from different batches but identical protocols regarding control and placebo treatment to enhance the statistical strength of the study, as they were identical in terms of handling and treatment.
| Hemodynamic measurements, tissue collection, and histology examination
At the end of every experimental protocol, rats were anaesthetised The animals were then killed; tissues were collected, snap frozen, and stored at −80°C for biochemical measurements. Hearts were dissected and weighted, and the ratio of right ventricle to left ventricle plus the septum mass was used as an index of right ventricular hypertrophy (RVH, RV/LV+septum). The left lung and RV were fixed with 10% formalin in phosphate-buffered saline and processed for elastic Van Gieson (EVG) and H&E staining. Vessels less than 100 μm in peripheral lung were counted blindly under microscope (40×) and pulmonary vascular remodeling was expressed as the proportion of vessels with double elastic lamina (>50%) to total vessels counted (% total muscularised vessels). 28 AxioVision software (Carl Zeiss, Oberkochen, Germany) was used to quantifying RV cardiomyocyte cross-section area (CSA) and myocyte diameter from transversely cut cardiomyocytes (n ≥ 30) at the level of nucleus from 3 different sections chosen randomly from each ventricle, using H&E staining.
| Biochemical measurements
| BH 4 levels
Measurements of BH 4 and BH 2 in lung and heart tissue were performed by HPLC analysis, after iodine oxidation in acidic or alkaline conditions as previously described. 17 All measurements of BH 4 were performed in collaboration with Prof K.M. Channon's group, Oxford University, UK.
| Western Blot analysis
Lungs were homogenized in extract buffer (RIPA). Protein concentration was measured by BCA protein assay. Protein lysates (20 μg) were resolved using SDS-PAGE and transferred to nitrocellulose mem- eNOS expression was normalized to β-actin.
| cGMP analysis
Lung cGMP levels were measured by cGMP Enzymeimmunoassay Biotrak (EIA) System (GE Healthcare) according to the manufacturer's instructions.
| Nitrate/Nitrite (NO x ) analysis
The final products of NO in vivo are nitrite (NO Arbor, MI, USA) by implying the principle of Griess reagents, according to the manufacturer's instructions. The first step in measuring NO metabolites is to convert nitrate in the sample into nitrite, using nitrate reductase. The second step is to add the Griess reagents, which convert nitrite into a deep purple azo compound. Photometric measurement of the absorbance due to the azo chromophore determines nitrite concentration.
| Superoxide levels
Total lung superoxide production was measured by lucigenin-enhanced chemiluminescence 29 as previously described. 17 Briefly, frozen lungs were homogenized in Krebs-HEPES buffer. Samples of homogenate corrected for total protein content were added to 2 mL Krebs-HEPES buffer containing lucigenin (5 μmol/L) in a scintillation vial at 37°C. O 
| Statistical analysis
In all experiments, results are expressed as mean ± SEM, N equals the number of animals per experiment. Statistical analysis was performed using unpaired t test when appropriate, nonparametric test with MannWhitney modification, or 1 way ANOVA when applied to multiple group comparisons. A value of P < .05 was considered statistically significant.
| RESULTS
| Genetic deficiency of BH 4 : the hph-1 mice
Hph-1 and heterozygous mice exhibited significantly elevated RVSP compared with WT controls (WT n = 9, Hetero n = 8, hph-1 n = 5).
The myocyte average diameter (indicator of RVH) was significantly bigger in both heterozygous and hph-1 mice compared with wild-type controls (Figure 1 ).
| Acute pharmacological effects of BH 4 rat model of MCT-induced PH
| BH 4 causes acute pulmonary vasodilation
In vivo BH 4 administration (1 mg bolus) caused minimal change in PAP in control rat (from 22.9 to 20 mm Hg), but a acute reduction in MCT animal model (from 36 to 18 mm Hg, Figure 2 and Table 1 ).
| BH 4 regulates cardiac contractility
In vitro hemodynamics using a Langendorff heart preparation, BH 4 increased RVSP in a state of RVH compared to control (ΔRVSP = 5.7 ± 1.3 mm Hg vs 0.7 ± 1 mm Hg, respectively, P < .05) as well as enhanced contractility in a state of RVH compared to control (Δdp/dt max = 640 ± 247 vs 261 ± 173 mm Hg/sec, P < .05, n = 3 in RVH, n = 4 in controls, Figure 3 ).
| Chronic pharmacological effects of BH 4 in rat model of MCT-induced PH
| BH 4 treatment is safe and well tolerated
BH 4 treatment was well tolerated in both doses. The animals' daily behavior and well-being was comparable to normal. After an initial drop in BW due to initial fasting, the BW follow-up chart was similar to normal diet controls ( Figure S1 ). BH 4 treatment did not influence pulmonary or systemic hemodynamic parameters ( Figure S2 ).
| BH 4 prevents the development of PH
In vivo hemodynamics
MCT injection induced PH characterized by increased mPAP (17.8 ± 1.2 to 29.3 ± 5.2 mm Hg, P < .01, Figure 4B) , RVSP F I G U R E 1 Right ventricular systolic pressure (RVSP) and RV myocyte diameter are measured in wild-type (WT, n = 9), heterozygous (hetero, n = 8), and hph-1 (homozygous, n = 5) mice. *P < .05 compared to WT, **P < .01 compared to WT F I G U R E 2 This figure demonstrates real pressure traces, recording right ventricular and pulmonary pressures (RV, PA) in control animal (above) and MCT-induced PAH rat (below) (29.1 ± 3.4 to 49 ± 9.6 mm Hg, P < .01, Figure 4A ), and RVH (RV/ LV+septum 0.29 ± 0.03 to 0.47 ± 0.14, P < .01, Figure 4D ). BH 4 (10 and 100 mg/kg) reduced mPAP from 29.3 ± 5.2 to 21.7 ± 3.6 and 21.5 ± 2.3 mm Hg, respectively (P < .05), prevented MCT-induced increases in RVSP (levels were similar to control levels) as compared to placebo (49 ± 9.6 compared with 33.9 ± 7.4 and 29.7 ± 3.4 mm Hg, respectively, P < .01). BH 4 (10 mg/kg) attenuated RVH in comparison with placebo while the higher dose totally prevented it (0.36 ± 0.07 and 0.32 ± 0.01 vs 0.47 ± 0.14, respectively, P < .05). Treatment with BH 4 did not influence systemic blood pressure.
Histology BH 4 treatment (10 and 100 mg/kg) ameliorated vascular muscularization in comparison with placebo in a dose-dependent manner (78 ± 4% and 64 ± 4% vs 95 ± 4%, respectively, P < .01, Figure 5 ). The total left lung weight over body weight ratio was reduced in BH 4 -treated T A B L E 1 Summary of the effect of BH 4 administration on pulmonary pressure (PAP), systolic blood pressure (systolic BP), and heart rate (HR) in vivo in control animal compared to 4 week MCT-induced PAH rat (n = 1 for control and n = 1 for MCT rat, this is qualitative data and statistical analysis cannot be performed)
Representative traces of right ventricular pressures in normal controls and hypertrophied hearts (RVH) during baseline and after administration of BH 4 (10 μg/mL). Notice that BH 4 administration increased systolic pressure significantly only when administered to the hypertrophied hearts. (B) Bar graphs summarize the results of these experiments as the difference in right ventricular systolic pressure (RVSP), dp/dt maximum and minimum and heart rate 5 minutes after BH 4 administration (control n = 4, RVH n = 3, * P < .05 compared to control group) groups while dry to wet lung weight was similar, signifying reduced pulmonary edema, (n = 6 per group). A marked perivascular inflamma- 
| BH 4 ameliorates the development of PH
| DISCUSSION
In the current study, we have demonstrated that BH 4 prevented the development of PH in MCT model, and when given as a rescue therapy, BH 4 ameliorated the progression of the disease and partially reversed it. The mechanism of action of BH 4 is enhancing eNOS "coupled" activity manifested by increased NO and cGMP levels which and quantified by the lung weight to body weight ratio (E), while verifying lung wet to dry weight ratio was not different among MCT groups regardless of treatment (F), as well as accurate measurement of lung distal vascular muscularization (G). *P < .05 compared to placebo, # P < .05 compared to control. (n = 6 per group). Biochemical measurements of cGMP (H), eNOS protein (I), and BH 4 (J) in lung homogenates from the BH 4 preventive experiment in MCT model (n = 6 per group, *P < .05 compared to placebo, **P < .01 compared to placebo, production are increased. 12, 37 Furthermore, oxidative stress is involved in cardiac hypertrophy and dysfunction. 38 Through targeting both simultaneously, endothelial cell and cardiac dysfunction, 38 BH 4 provides a potential therapy in PH; this established our main hypothesis.
Genetic deficiency of BH 4 causes selective PH phenotype in hph-1 mice which are maintained after continuous breeding as previously described. 17 RVH in the hph-1 could result from (1) increased afterload; Acute pharmacological experiments in rats showed that administration of BH 4 caused pulmonary vasodilation in the MCT model and enhanced cardiac contractility in a state of RVH. Pulmonary vasodilation is one of the targeted therapeutic pathways in PH. 40 The fall in PAP after acute administration of BH 4 in the MCT-treated animal is most likely the result of vasorelaxation of constricted pulmonary vessels, rather than depression of cardiac output. The results of acute pulmonary vasodilation in MCT model support our previously published data in perfused lung system 19 conducted in mice. Improvement of right ventricular function is a major therapeutic goal in PH but has not been adequately addressed. 41, 42 Our work in isolated perfused heart shows that BH 4 increases contractility rather than depresses it in particularly a state of RVH.
Plenty of experiments showed that NOS is a key determinant of left ventricular function. 24, 39, 43 Whether NOS plays a similar function in the right ventricle remains to be determined. In pathological conditions such as LVH, eNOS is uncoupled and contributes to increased oxidative stress, cardiac remodeling, diastolic dysfunction, and hypertrophy. 44 BH 4 reversed remodeling and fibrosis in LVH. 38, 43, 45 In our MCT model, progressive pressure overload could similarly lead to eNOS uncoupling in the RV and consequently RVH. Acute administration of BH 4 improved contractility selectively in RVH and chronic administration reversed myocycte hypertrophy which is a critical precursor to the development of heart failure. 46 Biochemical studies in heart tissues would have further supported our hypothesis but were beyond the scope and limits of the current study.
Chronic pharmacological studies, similarly to other studies,
showed that BH 4 treatment is safe and well tolerated. 33, 41, [47] [48] [49] prevented the development of MCT-induced PH and ameliorated the progression of the disease when given as a rescue therapy. BH 4 therapy prevented deterioration of systemic blood pressure, which could be related to incipient advanced right heart failure. A reduction in eNOS protein levels is characteristic of endothelial injury and dysfunction 50 and effective treatments in the MCT model are associated with maintenance or increased levels of eNOS in the lung tissue. 51, 52 We found BH 4 to have endothelial protective effects which are manifested by maintained/increased eNOS levels, increased NO and cGMP production. It could be that the increase in eNOS expression 2 weeks after the MCT injection is a result of significant inflammation and also contributing to the small increase in NO and cGMP observed in lung homogenates, but a significant reduction in eNOS levels by the fourth week of disease is apparent. This reduction in eNOS was prevented with BH 4 therapy, and there was an increase in cGMP and NO with the higher dose of BH 4 . It was showed previously that BH 4 treatment reduces general oxidative stress via its antioxidant activity and eNOS coupling 19 and thus stabilizes eNOS mRNA levels which are diminished. [53] [54] [55] However, preservation or increased eNOS expression may be insufficient to protect vascular function; actually it may be harmful and leads to PH. 56 It is rather the stoichiometry of NOS:BH 4 which is critical to maintain normal homeostatic balance. The discrepancy between attenuated RV/(LV+septum) ratio and the reversal of RV myocyte diameter increase in the BH 4 -treated group is intriguing. The increase in ventricular mass is predominantly the result of the following: protein synthesis, the addition of sarcomeres, 57 the development of cardiac progenitor cells into cardiomyocytes 58, 59 and finally, paralleled extracellular matrix synthesis and growth of the supporting vasculature. All these parameters are reflected in the RV/ (LV+septum) ratio index but not the RV myocyte diameter which could F I G U R E 7 The effect of BH 4 on distal lung vascular muscularization in MCT rescue study (A). Measurement and calculation of the impact of BH 4 on the degree of lung muscularization are represented in bars (B). **P < .01 compared to placebo, ***P < .001, # P < .05 compared to control. (n = 8-14 per group). Myocyte diameter is measured in right ventricle sections in different groups as an index of right ventricular hypertrophy (RVH) (C). **P < .01 compared to placebo, +P < .05 compared to 2 weeks MCT, # P < .05 compared to control. . n = 6 per group. *P < .05 compared to placebo. Furthermore, the effects of BH 4 treatment on levels of eNOS protein expression in lung homogenates in MCT rescue protocol are shown in (E) (n = 6 per group, *P < .05 compared to placebo, # P < .05 compared to control). Finally, the effect of BH 4 rescue treatment on BH4 levels in RV tissue of MCT model of PH is shown in (F). n = 6 per group. *P < .05 compared to placebo , ***P < .001 as well as measurement of MMPs in lung tissues of our MCT animal model would have provided important information to the therapeutic effects of BH 4 , and it will be addressed in future studies.
Our data are not without limits. Firstly, the data obtained from animal models of PH have its limits as readout of the complex human condition. Secondly, BH 4 treatment did not affect superoxide levels in lung homogenates. This could be a result of a dilutional effect of the whole tissue homogenate which will mask significant change in the targeted pulmonary vessels. Another method such as Dihydroethidium Fluorescent Microtopography could have been informative. Furthermore, superoxide is part of the reactive oxygen species (ROS) load together with hydroxyl radical, peroxynitrite and others, all of which BH 4 scavenges and thus a total measurement of ROS could have been relevant. Finally, biochemical studies would be important to delineate the mechanism of BH 4 therapy in reversing RVH and improving its contractility.
| CONCLUSIONS
The current study evaluates the efficacy of BH 4 treatment in MCT model as a potential therapy for PH (Figure 9 ). BH 4 addresses the vasoconstrictive, hyperproliferative, and hypertrophic nature of the disease, both in the lungs and the heart. The results of the current study supported the conduction of the recently published safety study of BH 4 in human PH which showed safe administration and significant improvement in 6-minute walk exercise test 63 and further supports future double-blind placebo-controlled studies of BH 4 in human PH.
It also opens the gate for possible therapeutic effects of BH 4 on right ventricular failure.
F I G U R E 9
A summary graph demonstrating the pathophysiology, hypothesis and therapeutic targets of BH 4 and the resultant prevention, amelioration and reversal of PAH
